Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-0184 in Healthy Participants
NCT06655870Phase 1Recruiting
- Sponsor
- Moderna Inc
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of mRNA-0184 in heart failure (HF) (2 arms), sponsored by Moderna Inc. Primary endpoint: Number of Participants with Treatment-emergent Adverse Events. Started Oct 2024; status: recruiting.
02
Drugs
mRNA-0184
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06655870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06655870.